纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | F11 |
Uniprot No | P03951 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 19-625aa |
氨基酸序列 | ECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV |
预测分子量 | 69.4 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于F11重组蛋白的3篇参考文献示例(内容基于虚构摘要,仅供参考):
---
1. **文献名称**: *Recombinant F11 Protein Modulates Endothelial Cell Adhesion and Barrier Function*
**作者**: Smith A, et al.
**摘要**: 研究通过表达重组F11蛋白,揭示其通过调控细胞间连接蛋白(如JAM-A)影响内皮细胞黏附和屏障完整性,为血管通透性疾病提供潜在治疗靶点。
2. **文献名称**: *Expression and Functional Characterization of Recombinant Coagulation Factor XI in Mammalian Cells*
**作者**: Chen L, et al.
**摘要**: 报道了在CHO细胞中重组表达人凝血因子XI(F11),验证其促凝血活性及结构稳定性,为血友病治疗药物开发奠定基础。
3. **文献名称**: *Role of Recombinant F11/JAM-A in Tumor Cell Migration and Metastasis*
**作者**: García-Rico E, et al.
**摘要**: 利用重组F11蛋白体外实验证明,其通过与整合素相互作用促进肿瘤细胞迁移,提示F11可能在癌症转移中发挥关键作用。
---
**注**:以上文献为示例,实际引用时需通过PubMed、Google Scholar等平台检索真实文献(关键词如"recombinant F11/JAM-A"或"recombinant factor XI")。若需具体文章,可提供更详细的研究方向。
**Background of F11 Recombinant Protein**
F11 recombinant protein, derived from the F11 gene (also known as *F11R* or *JAM-A*), is a biologically engineered molecule with significant roles in cellular adhesion and signaling. The F11 gene encodes junctional adhesion molecule-A (JAM-A), a transmembrane glycoprotein belonging to the immunoglobulin superfamily. JAM-A is primarily expressed on endothelial and epithelial cells, platelets, and leukocytes, where it regulates tight junction formation, leukocyte transmigration, and platelet activation. Its extracellular domain mediates homophilic and heterophilic interactions, while its cytoplasmic tail interacts with intracellular scaffolding proteins, linking it to signaling pathways.
The development of recombinant F11 protein emerged from the need to study JAM-A's functional mechanisms and therapeutic potential. Researchers utilize recombinant F11 protein produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) to investigate its role in inflammation, thrombosis, and cancer metastasis. For instance, studies have shown that F11/JAM-A overexpression correlates with enhanced tumor cell proliferation and migration, while its inhibition reduces pathological angiogenesis.
In therapeutics, recombinant F11 protein serves as a tool for blocking JAM-A interactions in inflammatory diseases or thrombosis. Its application in preclinical models has demonstrated efficacy in attenuating neutrophil infiltration in ischemic injury and limiting platelet aggregation. However, challenges remain in optimizing its stability, specificity, and delivery for clinical use. Recent advances in protein engineering, such as site-specific mutagenesis and fusion tags, aim to enhance its functional properties. Overall, F11 recombinant protein represents a versatile research and therapeutic agent with broad implications in vascular biology and disease intervention.
×